R
Ruud Oerlemans
Researcher at VU University Medical Center
Publications - 26
Citations - 1497
Ruud Oerlemans is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Bortezomib & Proteasome inhibitor. The author has an hindex of 15, co-authored 26 publications receiving 1392 citations. Previous affiliations of Ruud Oerlemans include VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans,Niels E. Franke,Yehuda G. Assaraf,Jacqueline Cloos,Ina van Zantwijk,Celia R. Berkers,George L. Scheffer,Kabir Debipersad,Katharina Vojtekova,Clara Lemos,Joost W. van der Heijden,Bauke Ylstra,Godefridus J. Peters,Gertjan L. Kaspers,Ben A. C. Dijkmans,Rik J. Scheper,Gerrit Jansen +16 more
TL;DR: A novel mechanism of bortezomib resistance associated with the selective overexpression of a mutant PSMB5 protein is established and is established in human myelomonocytic THP1 cells by exposure to stepwise increasing concentrations of bortsomib.
Journal ArticleDOI
Effect of age on functional P‐glycoprotein in the blood‐brain barrier measured by use of (R)‐[11C]verapamil and positron emission tomography
Rolf Toornvliet,Bart N.M. van Berckel,Gert Luurtsema,Mark Lubberink,Albert A. Geldof,Tessa M. Bosch,Ruud Oerlemans,Adriaan A. Lammertsma,Eric J.F. Franssen +8 more
TL;DR: The aim of this study was to assess the effect of aging on BBB P‐gp function and the relationship between BBBP‐gp activity and peripheral P‐ gp activity in CD3‐positive leukocytes was investigated.
Journal ArticleDOI
Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients.
Joost W. van der Heijden,Ruud Oerlemans,Ben A. C. Dijkmans,Huiling Qi,Conny J. van der Laken,Willem F. Lems,Ann L. Jackman,Maarten C. Kraan,Paul P. Tak,Manohar Ratnam,Gerrit Jansen +10 more
TL;DR: Abundant FRbeta expression on activated macrophages in synovial tissue from RA patients deserves further exploration for selective therapeutic interventions with high-affinity-binding folate antagonists, of which BCG 945 may be a prototypical representative.
Journal ArticleDOI
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Sue Ellen Verbrugge,Yehuda G. Assaraf,Ben A. C. Dijkmans,George L. Scheffer,Marjon Al,Debby den Uyl,Ruud Oerlemans,Elena T. Chan,Christopher J. Kirk,Godefridus J. Peters,Joost W. van der Heijden,Tanja D. de Gruijl,Rik J. Scheper,Gerrit Jansen +13 more
TL;DR: The results indicate that the pharmacologic activity of these PIs may be hindered by drug resistance mechanisms involving PSMB5 mutations and PI extrusion via Pgp, and drug efflux mediated by ATP-binding cassette transporters.
Journal ArticleDOI
ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer.
Rieneke van de Ven,Ruud Oerlemans,Joost W. van der Heijden,George L. Scheffer,Tanja D. de Gruijl,Gerrit Jansen,Rik J. Scheper +6 more
TL;DR: This review will focus on the expression, regulation, and substrate specificity of ABC transporters in relation to functional activities of immune effector cells and discusses implications for the treatment of cancer on the one hand and autoimmune diseases on the other.